Brokers Offer Predictions for Zentek’s Q2 Earnings (CVE:ZEN)

Zentek Ltd. (CVE:ZEN) – Investment analysts at Atrium Research issued their Q2 2027 earnings per share (EPS) estimates for shares of Zentek in a research note issued on Monday, September 14th. Atrium Research analyst B. Pirie forecasts that the mining company will earn ($0.01) per share for the quarter. Atrium Research has a “Strong-Buy” rating on the stock. The consensus estimate for Zentek’s current full-year earnings is ($0.10) per share. Atrium Research also issued estimates for Zentek’s Q3 2027 earnings at ($0.01) EPS, Q4 2027 earnings at ($0.01) EPS, FY2027 earnings at ($0.05) EPS and FY2028 earnings at ($0.05) EPS.

Zentek Trading Up 1.3%

Shares of Zentek stock opened at C$0.77 on Wednesday. The firm has a market cap of C$97.50 million, a PE ratio of -7.94 and a beta of 0.33. The stock has a fifty day moving average price of C$0.78 and a 200-day moving average price of C$0.77. The company has a debt-to-equity ratio of 7.62, a current ratio of 4.65 and a quick ratio of 7.59. Zentek has a 1 year low of C$0.52 and a 1 year high of C$1.50.

About Zentek

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It is also developing graphene oxide synthesis and graphene synthesis. In addition, the company owns 100% interest in the Albany graphite project located in Northern Ontario, Canada.